The European Union has established stringent regulations for General-Purpose AI models to address the risks associated with updates and ensure compliance through detailed documentation, risk assessments, and ongoing monitoring, particularly for systems classified as high-risk or systemic.
The US House of Representatives has passed the One Big Beautiful Bill Act, which includes a proposed 10-year federal moratorium on state and local regulations of AI systems, aiming to centralize oversight and address the fragmented regulatory landscape, despite significant opposition from various stakeholders concerned about consumer protections.
The US Department of Commerce’s Bureau of Industry and Security has rescinded the Artificial Intelligence Diffusion Framework, replacing it with new guidance addressing national security risks associated with AI technologies, particularly concerning transactions involving advanced semiconductors and Chinese technology firms.
The FDA is evolving its regulatory approach to accommodate AI and machine learning technologies in the medical field, emphasizing global harmonization and the need for increased expertise to manage the growing influx of AI-enabled applications.
The fourth annual AI Health Law & Policy Summit, hosted by Hogan Lovells and the AI Health Care Coalition, focused on critical legal and policy issues related to AI in healthcare, including data privacy, reimbursement challenges, and the evolving regulatory landscape involving CMS standards.
The OECD AI Principles, endorsed by over 40 countries, provide a framework for ethical AI development, emphasizing accountability, data governance, and human-centered values while addressing key policy areas such as risk management and privacy.
